We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is looking to make inroads in the lucrative obesity market.
The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio.
The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.
More on REGN’s Deal With Hansoh Pharma
Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau.
Per the terms of the agreement, Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achievement of development, regulatory and sales milestones. Any royalties on global net sales in the future (outside the designated territories) would be in the low double digits.
HS-20094 has been evaluated in over 1,000 patients and administered as a weekly subcutaneous injection. The candidate has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist.
The candidate is currently being evaluated in a phase III study in obesity in China, and a phase IIb study in diabetes is ongoing.
Regeneron Looks to Diversify Portfolio
The in-licensing agreement for an obesity candidate will expand REGN’s obesity pipeline, which includes trevogrumab.
Regeneron recently announced positive interim results from the ongoing phase II COURAGE study investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity.
COURAGE was designed to investigate the quality of weight loss in patients with obesity. Results showed that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass.
Garetosmab is being evaluated for the treatment of fibrodysplasia ossificans progressive.
The successful development of any obesity treatment will be a great boost for the company.
We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi (SNY - Free Report) reported results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD).
While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same.
REGN and SNY are currently reviewing the data and plan to discuss the next steps with regulatory authorities.
Year to date, REGN’s shares have lost 31.7% compared with the industry’s 3.2% decline.
Image Source: Zacks Investment Research
Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line.
Eylea sales have been under pressure for some time now due to competition from Roche’s Vabysmo.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line.
Apart from Eylea, profits from the sales of asthma drug Dupixent are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for Dupixent.
While the obesity market is lucrative, REGN is a pretty late entrant here. The market is dominated by bigwigs like Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) .
The stupendous success of Novo Nordisk’s obesity drug, Wegovy (semaglutide) and Eli Lilly’s Zepbound has prompted many companies to join the bandwagon.
Buoyed by this success, both Lilly and NVO have taken significant strides in developing their obesity portfolios further. Given the significant market potential of obesity, other players are also striving to grab a chunk of this pie.
Image: Bigstock
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
Key Takeaways
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) is looking to make inroads in the lucrative obesity market.
The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio.
The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.
More on REGN’s Deal With Hansoh Pharma
Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau.
Per the terms of the agreement, Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achievement of development, regulatory and sales milestones. Any royalties on global net sales in the future (outside the designated territories) would be in the low double digits.
HS-20094 has been evaluated in over 1,000 patients and administered as a weekly subcutaneous injection. The candidate has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist.
The candidate is currently being evaluated in a phase III study in obesity in China, and a phase IIb study in diabetes is ongoing.
Regeneron Looks to Diversify Portfolio
The in-licensing agreement for an obesity candidate will expand REGN’s obesity pipeline, which includes trevogrumab.
Regeneron recently announced positive interim results from the ongoing phase II COURAGE study investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab (anti-activin A) for the treatment of obesity.
COURAGE was designed to investigate the quality of weight loss in patients with obesity. Results showed that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass, and further demonstrated that combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while increasing loss of fat mass.
Garetosmab is being evaluated for the treatment of fibrodysplasia ossificans progressive.
The successful development of any obesity treatment will be a great boost for the company.
We note that REGN has had a rough time so far this year. The stock got hammered last week after REGN and partner Sanofi (SNY - Free Report) reported results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease (COPD).
While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same.
REGN and SNY are currently reviewing the data and plan to discuss the next steps with regulatory authorities.
Year to date, REGN’s shares have lost 31.7% compared with the industry’s 3.2% decline.
Image Source: Zacks Investment Research
Regeneron's performance in the first quarter was dismal. The plunge in Eylea sales adversely impacted the top line.
Eylea sales have been under pressure for some time now due to competition from Roche’s Vabysmo.
Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote
Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line.
Apart from Eylea, profits from the sales of asthma drug Dupixent are a primary growth driver for REGN. Regeneron has a collaboration agreement with Sanofi for Dupixent.
While the obesity market is lucrative, REGN is a pretty late entrant here. The market is dominated by bigwigs like Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) .
The stupendous success of Novo Nordisk’s obesity drug, Wegovy (semaglutide) and Eli Lilly’s Zepbound has prompted many companies to join the bandwagon.
Buoyed by this success, both Lilly and NVO have taken significant strides in developing their obesity portfolios further. Given the significant market potential of obesity, other players are also striving to grab a chunk of this pie.
REGN Rank
Regeneron currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.